Published:
Kendle Invites You to Attend its First Quarter 2008 Earnings Conference Call and Webcast
CINCINNATI, April 24 /PRNewswire-FirstCall/ --
CALL DATE: Wednesday, May 7, 2008
TIME: 9:30 a.m. Eastern Time
HOST: Dr. Candace Kendle, Chairman and CEO
Kendle (Nasdaq: KNDL) will conduct a telephone conference call and
simultaneous webcast on Wednesday, May 7 at 9:30 a.m. Eastern Time to discuss
its financial results for the First Quarter ended March 31, 2008. A question
and answer session will follow.
Webcast Instructions
To access the live webcast, go to http://www.kendle.com or
http://www.videonewswire.com/event.asp?id=47950. Instructions for accessing
the webcast are provided at both sites. The webcast will be archived at
http://www.kendle.com (click on "Investors" and then "Events & Presentations")
shortly after the call for on-demand replay through 5 p.m. Eastern Time on
June 6, 2008. Please note that webcast participants will not be able to ask
questions.
System requirements for the webcast include Windows Media Player software
and at least a 28.8 Kbps connection to the Internet. Media Player is
downloadable at no charge from
http://www.microsoft.com/windows/windowsmedia/default.aspx.
Conference Call Instructions
To register (RSVP) for the telephone conference call, U.S. and Canadian
participants should dial (800) 223-7104. Participants outsideNorth America
should dial (706) 645-6519.
To participate in the telephone conference call, interested parties inthe
United States andCanada should dial (800) 399-0069. Participants outside
North America should dial (706) 643-3694. A replay will be available through 5
p.m. Eastern Time on June 6 by dialing (706) 645-9291 and entering conference
ID number 41241978.
About Kendle
Kendle (Nasdaq: KNDL) is a leading global clinical research organization
providing the full range of early- to late-stage clinical development services
for the world's biopharmaceutical industry. Our focus is on innovative
solutions that reduce cycle times for our customers and accelerate the
delivery of life-enhancing drugs to market for the benefit of patients
worldwide. As one of the fastest-growing global providers of Phase I-IV
services we offer experience spanning 90 countries, along with
industry-leading patient access and retention capabilities and broad
therapeutic expertise, to meet our customers' clinical development challenges.
Kendle was named "Top CRO to Work With" in the Thomson CenterWatch 2007 survey
of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading global
pharmaceutical publication Scrip World Pharmaceutical News.
Additional information and investor kits are available upon request from
Kendle, 441 Vine Street, Suite 1200,Cincinnati, OH 45202,United States or
from the company's Web site at http://www.kendle.com
(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )
SOURCE Kendle
Copyright © 2009, PRNewswire
Copyright © 2009, NewsBlaze,
Daily News
Tags: ,HEA,MTC,BIO,CCA,OH-Kendle-Q1-confcall